Rovaldi Christopher 4

4 · Keros Therapeutics, Inc. · Filed Apr 5, 2022

Form 4

Period: 2022-04-01

Chief Operating Officer

Transactions

Sale
Common Stock
2022-04-01$54.34/sh−2$109→ 862 total
Sale
Common Stock
2022-04-01$56.20/sh−104$5,845→ 758 total
Sale
Common Stock
2022-04-01$56.89/sh−287$16,327→ 471 total
Exercise/Conversion
Common Stock
2022-04-01$16.00/sh+864$13,824→ 864 total
Sale
Common Stock
2022-04-01$57.97/sh−366$21,217→ 105 total
Sale
Common Stock
2022-04-01$58.83/sh−105$6,177→ 0 total
Exercise/Conversion
Employee Stock Option (right to buy)
2022-04-01−864→ 9,730 total
Exercise: $16.00Exp: 2030-04-07→ Common Stock (864 underlying)

Footnotes (6)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.50 to $56.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $57.43 inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.58 to $58.26 inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.62 to $59.275 inclusive.
[F6]One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

Documents

1 file